Lupin’s partnered biosimilars program has delivered its first filing in Japan, marking a significant milestone for the Indian company as it shifts gears to more complex products and plays catch-up with some peers in the biologics space.
Lupin Ltd. and Yoshindo's joint venture, YL Biologics, has filed a New Drug Application (NDA) with the Pharmaceuticals and...